Search form

Intended Use For Research Use Only. Not for use in diagnostic procedures.
Catalog Number A239
Price $313.00 (U.S. List Price)
Size 100 µL
Application EIA, FACS, IHC, RIA, WB
Buy Now         Request Info

Description

For Research Use Only. Not for use in diagnostic procedures.

A murine monoclonal antibody to a neoantigen on the terminal complement complex.

This monoclonal antibody was raised against purified human C9. This antibody has been shown to bind to a neoantigen expressed on SC5b-9, TCC, MAC, poly- C9 and on denatured immobilized C9.

Quidel's TCC monoclonal antibody has been used in a variety of experimental techniques including EIA, Western Blot, and Immunohistochemistry. Please contact Quidel Technical Support for details on these or other applications.

References

8 References

TScambi C, Ugolini S, Jokiranta TS, De Franceschi L, Bortolami O, et al. (2015) The Local Complement Activation on Vascular Bed of Patients with Systemic Sclerosis: A Hypothesis-Generating Study. PLOS ONE 10(2): e0114856.

Loeffler DA, Camp DM, Bennett DA. Plaque complement activation and cognitive loss in Alzheimer’s disease. Journal of Neuroinflammation. 2008;5:9.

Merri, A., Junnikala, S. Exceptional Resistance of Human H2 Gioblastoma Cells to Complement Mediated Killing by Expression and Utilization of Factor H and Factor H Like Protein 1, J Immunol 164:11 6075-6081, 2000.

Stoltzner, S., Lemerre, C. et al. Temporal accrual of complement proteins in Amyloid plaques in patients with down's syndrome with Alzheimer's Disease, Am J Path 156:489-499, 2000.

Wright, A., Morrison, S. Effect of C2 Associated Carbohydrate structure of Ig Effector function: studies with chimeric mouse human IgG1 Antibodies in glycosylation mutants of chinese hamster ovary cells, J. Immunol 160:3393-3402, 1998.

Gemmell, C. A flow cytometric immunoassay to quantify adsorption of complement activation products on artificial surfaces, J Biomed Mater Res 37, 474-480, 1997.

Rogers, J., N. Cooper, et al. Complement Activation by ß-amyloid in Alzheimer disease, PNAS 89:10016-10020, 1992.

Depisch, R. V. Schmitt et al. Fluid phase generation of terminal complement complex as a novel index of bio-incompatibility, Kidney Int'l, 37, 696-627 1990.

Features & Benefits

FeatureBenefit

Product Specifications

Product Spec NameProduct Spec Data
Isotype

IgG2bk

Protein concentration

> 1.0 mg/mL

Volume/vial

100 µL

Storage

2°C to 8°C

Ordering Information

Catalog NumberKit Size / Case Size
A239
100 µL

Product Documentation